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This study aimed to investigate lymphedema prevalence using three different measurement/diagnostic criterion combinations and
explore the relationship between lymphedema and quality of life for each, to provide evaluation of rehabilitation. Cross-sectional
data from 617 women attending review appointments after completing surgery, chemotherapy, and radiotherapy included the
Morbidity Screening Tool (MST; criterion: yes to lymphedema); Lymphedema and Breast Cancer Questionnaire (LBCQ; criterion:
yes to heaviness and/or swelling); percentage limb volume difference (perometer: %LVD; criterion: 10%+ difference); and the
Functional Assessment of Cancer Therapy breast cancer-specific quality of life tool (FACT B+4). Perometry measurements were
conducted in a clinic room. Between 341 and 577 participants provided sufficient data for each analysis, with mean age varying
from 60 to 62 (SD 9.95–10.03) and median months after treatment from 49 to 51. Lymphedema prevalence varied from 26.2% for
perometry %LVD to 20.5% for the MST and 23.9% for the LBCQ; differences were not significant. Limits of agreement analysis
between %LVD and the subjective measures showed little consistency, while moderate consistency resulted between the subjective
measures. Quality of life differed significantly for women with and without lymphedema only when subjective measurements were
used. Results suggest that subjective and objective tools investigate different aspects of lymphedema.
1. Introduction
Progressions in the treatment of breast cancer have led to
increased survival rates and increased emphasis on improv-
ing outcomes and quality of life in the long term through
targeted rehabilitation. Lymphedema is a condition that can
develop early or years after treatment, due to the necessary
rigor of surgery and radiotherapy which can interrupt the
lymphatic system to varying degrees depending on the type
of surgery and the dose of radiotherapy [1]. As a result,
interstitial tissue can accumulate in the tissues, leading to skin
fibrosis and cellulitis.There is evidence of substantial impacts
of lymphedema on quality of life and functional outcomes
[2]. There is evidence to support rehabilitation interventions
specific to the management of lymphedema as a long-term
condition, which are summarized in an international consen-
sus document; they include skin care, specialized massage,
sustained compression, and exercise [3]. When lymphedema
is detected early, therapeutic management is more likely to be
effective [4].
The incidence of lymphedema is likely to be affected by
the increasing use of less conservative surgical techniques for
breast cancer, such as breast-conserving surgery and sentinel
lymph node biopsy, although this may also increase the use
of axillary radiotherapy [5]. Researchers have investigated
different possible risk factors for the development of lym-
phedema; a systematic review of prevalence and risk factors
found the former to range from 0 to 34%. It established
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a pooled odds ratio for developing lymphedema of 1.46
(95% CI 1.16–1.84; 8 studies) for patients who have received
radiotherapy compared to those who have not [6]. No
differences were found in risk when comparing mastectomy
with breast-conserving surgery in only three studies, but
lymphedema was 11.67 times more likely (95% CI 1.45–93.65;
3 studies) where full axillary lymph node dissection (ALND)
was conducted, compared with sentinel lymph node biopsy
(SLNB). In one cross-sectional study comparing these two
surgical procedures lymphedema prevalence associated with
ALND was 43.3% and with SLNB was 22.2% (𝑛 = 102) [7].
A prospective study of 936 women evaluated five years after
surgery found self-reported arm swelling in 3% of patients
after SLNB and 27% with SLNB/ALND and objectively
measured lymphedema of 5% and 16%, respectively [8].
Although prevalence estimates vary, it appears that SLNB
poses a lower risk of lymphedema, supporting its use.
In order to assist developments in breast cancer treatment
and subsequent rehabilitation, it is very important to estimate
prevalence after different types of treatment and to monitor
lymphedema over time. However, currently there is wide
variability in prevalence estimates, from 2 to 86%, resulting
from study samples with different treatment characteristics,
the use of different measurements, and varied diagnostic
criteria [5].
When considering measurement of lymphedema, most
objective tools focus on limb volume. Volumetry (water
displacement) was considered the gold standard until fairly
recently but was not practical clinically, and instead, circum-
ferential measurement of limb segments was used, alongside
geometric formulae to enable estimation of volume. More
recently, however, perometry (opto-electronic scanning) and
multifrequency bioelectrical impedance measurements have
gained in popularity as they aremore reliable, fast to conduct,
and hygienic [1, 9].When using this form of tool, diagnosis of
lymphedema ideally relies on comparisons between pre- and
postsurgicalmeasurements, although in cross-sectional stud-
ies bilateral limb comparisons are usually made. Differences
seen to indicate lymphedema vary, most commonly stated to
be equal to or greater than 10% or 200mL limb volume or
2 cm or 5 cm differences in limb circumference [10, 11].
There is evidence to suggest that subjective assessment
through patient self-report is more sensitive to the develop-
ment of lymphedema, as well as being less expensive [1, 5, 11].
Diagnosis of the condition usually focuses on the presence
of specific symptoms, such as “heaviness” or “swelling.”
They also address functional and psychosocial aspects of the
condition rather than focusing on physical dimensions. A
combined approach is recommended by some [1].
Some studies report good correlations between mea-
surement methods such as circumferential and volumetry
measurements, but these do not agree and cannot be used
interchangeably.They also focus onmeasurement of variables
such as limb volume rather than estimation of incidence or
prevalence [12, 13].
One study demonstrated the impact of the classification
or diagnostic criterion used with a single objective measure;
sequential arm circumference measurement in 347 women
was conducted twelve months after surgery [14]. Prevalence
of 11% was found within the sample when lymphedema was
defined as 2 cm or greater difference between limbs at any
measurement point. Limb volume was calculated based on a
truncated cone formula, and prevalence differed when using
the criteria of 150mL or greater difference between limbs
(9%) and 5% or greater (16%).
A small number of studies have compared prevalence of
lymphedema within samples estimated using different tools
and diagnostic criteria. One study compared limb volume
changes before surgery to those 12 months after diagnosis
in 118 participants, using perometry, circumferential mea-
surement, and self-report [11]. Twelve-month prevalence
estimates varied from 21% to 70%prevalence, with perometry
measurement (10% or greater change in limb volume) found
to be the most conservative and 2 cm difference in limb cir-
cumferencemost sensitive.The same research group followed
up 211 women 2.5 years after treatment and again found 2 cm
difference in circumferences to be the most sensitive (91%)
but found self-report to be the most conservative (41%) [15].
One further study of 176 women found higher estimation by
self-report (27.9%) than by objective criteria, which varied
between 0.6% (10% or greater difference in summed arm cir-
cumference), 11.4% (multifrequency bioimpedance: 3 ormore
SD above the reference score), and 11.9% (5 cm or greater
difference in summed armcircumference) [10].Therefore, the
literature does not demonstrate consensus regarding whether
subjective or objective measures provide higher estimates of
lymphedema prevalence, or the most valid.
With no gold standard for measuring and classifying
lymphedema, it is difficult to know which method produces
the most valid prevalence estimate. One way of investigating
this is to look at how a construct expected to vary with
lymphedema incidence, such as quality of life, relates to
estimates provided by different systems of measuring and
classifying lymphedema. Indicators of quality of life, psy-
chological morbidity, depression and anxiety, and quality of
life scores have been found to differentiate between women
who have and do not have lymphedema after breast cancer
treatment [16, 17]. One study found that lymphedemawas the
strongest of three factors that were independently associated
with quality of life after treatment for breast cancer, along
with nonwhite race and postmenopausal status [18].
To conclude, it is important to understand the rela-
tionship between subjective and objective estimations of
lymphedema prevalence, to make future decisions relating
to choice of measurement tool and classification of lym-
phedema. This secondary data analysis addresses four main
questions: how do three different systems of measuring
and classifying lymphedema differ in their estimation of
prevalence?
(i) Do the three different systems of measuring and
classifying lymphedema identify the same subsample
of subjects as having lymphedema?
(ii) What are the sensitivity and specificity of the self-
reported systems in relation to the objective measure
(perometry) and classification of lymphedema?
(iii) Does the relationship of self-reported quality of life
with lymphedema differ when measured with three
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different systems of measuring and classifying lym-
phedema?
2. Methods
2.1. StudyDesign. This paper represents secondary analysis of
a dataset from a cross-sectional study which aimed to screen
for fatigue, impaired upper limb function, lymphedema, and
pain in women following treatment for breast cancer. It
was classified as service review by the South East Scotland
Research Ethics Committee and full ethical review was
carried out within the Higher Education Institution to ensure
that procedures were in accordance with their standards
(Declaration of Helsinki 1975, revised Hong Kong 1989).
2.2. Procedure. Subjective and objective measurements of
morbidity and quality of life were carried out on women
who provided informed consent to participate while awaiting
review appointments at the Breast Clinic. Women were
approached with information and consent form if they
had completed surgery (mastectomy or wide local excision;
lymph node clearance or either four-node axillary sam-
pling or sentinel lymph node biopsy), chemotherapy, and
radiotherapy (breast and/or axilla), did not have recurrence,
and could complete questionnaires in English. Consenting
participants completed questionnaires in the waiting room
and objective tests in a private clinic room. Medical records
were reviewed in order to obtain treatment characteristics.
The data used in this secondary analysis included three
measures of lymphedema and one of quality of life.
Quality of life was measured using the Functional Assess-
ment of CancerTherapy questionnaire with breast cancer and
arm function subscales (FACT B+4). There is evidence for
its reliability, validity, and practicality [19, 20]. A five-point
Likert scale is used, with greater quality of life correspond-
ing with a high score once negatively phrased item scores
are reversed. Scores are then calculated by summing the
subscale scores, providing physical well-being (PWB), social
well-being (SWB), emotional well-being (EWB) functional
well-being (FWB), and breast cancer additional concerns
subscales (BCC), plus the sum of four questions relating
to upper limb swelling and function (arm-specific subscale:
AS). All can be interpreted independently [21], and the Trial
Outcome Index (TOI) is the sum of the PWB, FWB, and BCC
subscales, found to be a better summary index for physical
and functional outcomes [19]. Where items are missing for
less than 50% of a subscale, the remaining item responses are
prorated by using the mean of the answers provided for that
subscale [19]. Overall, it is expected that an item response rate
of over 80% for the FACT G is achieved (sum of PWB, SWB,
EWB, and FWB).
Perometer (optoelectronic) measurement was used to
provide objective measurement of percentage difference in
upper limb volume (%LVD) between affected and unaffected
limbs. The vertical perometer (400 T) was used; there is
evidence for its validity and reliability in populations of
women after breast cancer and with known lymphedema [22,
23]. A standardised protocol was used to enhance reliability
(Bulley et al., unpublished data). The mean of three mea-
surements for each limb was used where available; the mean
of twomeasurements (in 16 cases) or use of onemeasurement
(in 3 cases) per limb was used if necessary. Where the %LVD
was 10% or greater, lymphedema was identified [11].
The subjective self-report Morbidity Screening Tool
(MST) was developed by the research group. This tool
includes a short form focusing on lymphedema; the first
question establishes whether or not a person perceives that
they have lymphedema (“yes” response), and subsequent
questions explore self-reported impacts on activities and
participation. The research team investigated its validity and
found evidence to support its use; further detail is available
elsewhere (Bulley et al., unpublished data). When focusing
on the initial question relating to presence or absence of
lymphedema, significantly greater %LVD (𝑛 = 434), FACT G
scores, and FACT B+4 arm-specific subscale scores (𝑛 = 613)
were found in those self-reporting lymphedema on the MST,
versus those who did not, in those with unilateral treatment
(%LVD: 𝑈 = 112128; 𝑝 < 0.001; FACT G: 𝑈 = 14617.0;
𝑝 < 0.001; FACT B+4 arm subscale: 𝑈 = 9671.5; 𝑝 < 0.001).
The second subjective measure was provided by the
Lymphedema and Breast Cancer Questionnaire (LBCQ), a
structured interview tool that evaluates 19 symptoms both
currently and in the past [1]. Face and content validity and
test-retest reliability have been supported and logistic regres-
sion found two items to be the best predictors of lymphedema
(limb circumference difference of 2 cm or more): “heaviness
in the past” and “swelling now” [1]. In the current study,
affirming one or both of these items was used as a criterion
for identifying or classifying lymphedema. If a participant
answered only one of the two items and negated it, the
presence of lymphedema according to the LBCQ could not be
established and the participant was excluded from analysis.
2.3. Analysis. Data were stored in an Access database; SPSS
was used to perform descriptive and inferential analysis.
Descriptive analysis was conducted using frequencies and
percentages where variables were categorical; means and
standard deviations for normally distributed continuous data
and medians and ranges for nonnormally distributed data.
Normality was tested using the Kolmogorov-Smirnov test.
In all inferential analysis, tests were two sided and statistical
significance was set at 𝑝 < 0.05.
All available data for each tool were used when determin-
ing prevalence estimates for each tool. When analyzing the
MST, nonrespondents to questions relating to lymphedema
were excluded from analysis, leaving 577 participants. Where
a participant had not answered one or both of the LBCQ
questions used to identify lymphedema, they were excluded
from analysis, leaving 410 people with available data. Bilateral
perometry data were available for 389 women.
The three lymphedema prevalence estimates were com-
pared using Cochran’s Q Test in 341 women who had
complete data for all three measures [24]. The proportion
of individuals who were identified as having lymphedema
by each of the three tools was identified and the Kappa
measure of agreement was used to investigate the consistency
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Table 1: Participant characteristics.
Participant characteristics
(𝑁 = number) MST
a (𝑁 = 577) LBCQb (𝑁 = 410) Perometry(𝑁 = 389)
Complete data for MSTa,
LBCQb, and perometry
(𝑁 = 341)
Age: mean (SDc) 62.21 (10.03) 60.99 (9.97) 60.97 (9.95) 60.49 (9.99)
Months since treatment:
median (range)
54 (0–360)
(𝑁 = 575 with data)
50 (0–360)
(𝑁 = 409 with data)
51 (0–360)
(𝑁 = 387 with data)
49 (0–360)
(𝑁 = 341 with data)
Wide local excision:𝑁 (%d) 412 (72.3% of 570) 292 (72.0% of 406) 269 (69.9% of 385) 238 (70.4% of 338)
Mastectomy:𝑁 (%d) 156 (27.4% of 568) 112 (27.8% of 404) 114 (29.8% of 384) 100 (29.6% of 337)
Axillary surgerye:𝑁 (%d) 292 (59.3% of 493) 218 (61.5% of 354) 231 (59.6% of 387) 179 (60.4% of 297)
Radiotherapy to the breast:𝑁 (%d) 474 (82.5% of 575) 336 (82.2% of 409) 317 (81.7% of 388) 278 (81.8% of 340)
Radiotherapy to the axilla:𝑁 (%d) 139 (24.3% of 574) 102 (25.1% of 408) 94 (24.4% of 387) 81 (23.8% of 339)
aMST: Morbidity Screening Tool.
bLBCQ: Lymphedema and Breast Cancer Questionnaire.
cSD: standard deviation.
d% frequency of number of participants with data for participant characteristic.
eAxillary surgery includes lymph node clearance, four-node sampling, and sentinel lymph node biopsy.
Table 2: Prevalence of lymphedema according to eachmeasurement
tool.
Method of
measurement
Prevalence: all available data for each tool
Number % frequency
Perometry 389 26.2
LBCQa 410 23.9
MSTb 577 20.5
Subjective (yes to either
LBCQa/MSTb/both) 577 27.2
aMST: Morbidity Screening Tool.
bLBCQ: Lymphedema and Breast Cancer Questionnaire.
of lymphedema identification. This compared two tools at
a time. Sensitivity and specificity of the two subjective
measures were investigated using the objective classification
or diagnostic criterion of 10% or greater LVD as a comparator.
The subjective tools were compared, using the more estab-
lished LBCQ as the criterion.
Analysis of the differences in quality of life between
women with and without lymphedema, according to each
measurement tool, was conducted in women with complete
data for both variables.Thiswas possible for 358womenwhen
analyzing perometry%LVD scores, 378 for the LBCQand 459
for the MST. Comparisons were conducted using t tests (two
sided) where data were continuous and normally distributed
and the Mann-Whitney U test where data were nonnormally
distributed. The Chi-square test was used where variables
were categorical.
3. Results
Participant characteristics for each dataset are provided in
Table 1 and demonstrate similarities among the available data
for each measurement tool. To give an indication of the time
periods over which treatments were carried out, data were
collected between November 2009 and May 2010, at which
point 93% of participants were within 10 years after treatment
(treatment betweenMay 2000 and November 2009) and 99%
were within 15 years after treatment (treatment between May
1995 and November 2009).
Table 2 summarizes prevalence of lymphedema, which
varied from 20.5% to 26.2%, with objective measurement
achieving the highest estimate and the MST achieving the
lowest. When considering all those responding positively
to either or both of the subjective tools, prevalence was
similar to the objective estimate. When comparing frequen-
cies of individuals identified as having lymphedema between
the measures, no significant difference was demonstrated
(Cochran’s 𝑄 = 1.504, 𝑝 = 0.471).
Consistency of identification of lymphedema between
measures was evaluated using the Kappa measure of agree-
ment between measurement pairs: a Kappa of 0.207 (𝑝 <
0.001) resulted between perometry and LBCQ; 0.143 (𝑝 =
0.008) between perometry and the MST; and 0.531 (𝑝 <
0.001) between the LBCQ and MST. This suggests moderate
agreement between the subjective tools, but poor agreement
between each subjective tool and perometry [24].
When evaluating sensitivity as the proportion of correctly
identified true positives and specificity as the proportion of
correctly identified true negatives [25], perometry %LVD
was used as the reference method. The LBCQ had 40.7%
sensitivity, compared to 36.8% for the MST—very similar.
Specificity was also similar for both subjective tools: 80.0%
and 78.1%, respectively. However, it is important to note that
less than 50% of lymphedema cases that were objectively
identified were also subjectively identified. About a fifth of
those without lymphedema according to perometry were
found to have lymphedema subjectively. Sensitivity and
specificity were found to be 69.0% and 88.2%, respectively
when comparing the MST to the LBCQ, higher between sub-
jective tools than when either was compared with perometry.
When comparing quality of life subscales and the FACT
B+4 TOI between those with and without lymphedema for
each measurement tool (Table 3), perometry classification
did not demonstrate significant differences in all except the
arm subscale of the FACT B+4, which includes a question
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Table 3: Differences in quality of life in those with and without lymphedema according to each measurement tool.
FACT B+4a subscales No lymphedema: median Lymphedema: median
Inferential analysis of difference:
the Mann-Whitney 𝑈 test
𝑍 value 𝑝 value
Analysis using Perometry data
TOIb (𝑛 = 357) 94 92 −0.829 0.407
PWBc (𝑁 = 359) 26 26 −0.623 0.533
SWBd (𝑁 = 356) 26 26 −0.329 0.742
EWBe (𝑁 = 357) 21 21 −0.536 0.592
FWBf (𝑁 = 359) 25 25 −0.151 0.880
BCCg (𝑁 = 357) 43 42 −1.64 0.100
ASh (𝑁 = 357) 20 18 −2.96 0.003∗
Analysis using LBCQi data
TOIb (𝑛 = 376) 95 84 −6.746 <0.005∗
PWBc (𝑁 = 378) 27 24 −6.158 <0.005∗
SWBd (𝑁 = 376) 27 24.5 −3.426 0.001∗
EWBe (𝑁 = 376) 21 20 −2.845 0.004∗
FWB f (𝑁 = 378) 25 22.5 −4.370 <0.005∗
BCCg (𝑁 = 376) 44 36 −7.449 <0.005∗
ASh (𝑁 = 376) 20 15 −9.774 <0.005∗
Analysis using MSTj data
TOIb (𝑛 = 453) 94 84.5 −6.445 <0.005∗
PWBc (𝑁 = 459) 26 24 −5.004 <0.005∗
SWBd (𝑁 = 454) 26 26 −1.234 0.217
EWBe (𝑁 = 456) 21 20 −1.510 0.131
FWB f (𝑁 = 459) 25 22.5 −3.382 0.001∗
BCCg (𝑁 = 453) 44 37 −7.698 <0.005∗
ASh (𝑁 = 453) 20 15 −10.279 <0.005∗
aFACT B+4: Functional Assessment of Cancer Therapy-Breast Cancer subscale.
bTOI: Trial Outcome Index.
cPWB: physical well-being.
dSWB: social well-being.
eEWB: emotional well-being.
fFWB: functional well-being.
gBCC: breast cancer specific concerns.
hAS: arm-specific subscale.
iMST: Morbidity Screening Tool.
jLBCQ: Lymphedema and Breast Cancer Questionnaire.
∗
𝑝 value is statistically significant.
about arm swelling. The subjective measures demonstrated
similar results to one another, with significant differences in
all FACT B+4 subscales and the TOI for the LBCQ and all
except SWB and EWB for theMST. Overall, where significant
differences exist in the sample, they appear to be the strongest
for the physical and functional subscales and the breast
cancer and arm-specific subscales.
To summarize, objective measurement provided the
highest prevalence estimate and theMST the lowest, although
no statistically significant differences were found. Poor agree-
ment between methods was found between subjective tools
and objective ones, while moderate agreement was found
between subjective tools. Sensitivity of the subjective tools,
compared with objective, was not high, while specificity was
better. Quality of life subscale scores did not differentiate
significantly between those with and without lymphedema
when using objective classification but did when using either
subjective tool.
4. Discussion
The variability in prevalence estimated using the three sys-
tems of measuring and classifying lymphedema is consistent
with previous results in this area [10, 11, 26], although
the relatively small and nonsignificant differences between
estimates are unexpected, with a range of only 5.7%. They
are less variable than results found in previous studies
that compare systems of measuring and classifying lym-
phedema within single samples. One study used perometry
with two diagnostic criteria: 200mL and 10% or greater
change; prevalence estimates at 12 months were 42% and
21%, respectively [11]. Circumferential measurements were
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used, with a classification criterion of 2 cm increase at a
single point, giving an estimate of 70% prevalence. Lastly,
the Lymphedema and Breast Cancer Questionnaire [1],
which diagnoses lymphedema if participants report signs
and symptoms of heaviness and swelling, gave a prevalence
estimate of 40%. A further study, with prevalence estimated
at 2.5 years after treatment, found that the same criterion
gave the highest estimate (2 cm difference in circumferences:
91%), but self-report gave the lowest estimate at 41% [15].
Estimates of 67% and 45% were found for 200mL change in
limb volume (perometry) and 10% or greater limb volume
change (perometry), respectively. However, further evidence
of greater prevalence estimation by self-report (27.9%) was
also found when compared with 11.9% for 5 cm or greater
difference in summed arm circumference, 0.6% for 10% or
greater summed arm circumference, and 11.4% according to
multifrequency bioimpedance, using a difference of 3 ormore
standard deviations above the reference score [10].
There is inconsistency in the existing literature as to
whether subjective or objective measures provide higher
prevalence estimates [10, 11, 15]. In the current study, objective
estimation was found to give the highest prevalence. No
other study has been located that compared two subjective
measures; it is noticeable that theMST, which utilizes a single
question relating to the presence or absence of lymphedema,
gave a lower prevalence estimate than the LBCQ, where
classification of lymphedema was made where a person
affirmed one or both of two separate items. Both included
a question relating to swelling, but only the LBCQ also
included alterations in the sensation of heaviness when
classifying lymphedema. Furthermore, the MST focuses on
self-report of sensations “at the moment (e.g., in the past
week),” while the LBCQ also addresses “in the past.” One
could argue that the latter would include people with swelling
that has resolved, which may not reflect chronicity. Some
participants were positively diagnosed with lymphedema
according to the MST, but not the LBCQ; this may relate to
the “cues” provided by the MST question (e.g., tight-fitting
rings or clothes), which are not provided in the specific items
of “swelling” and “heaviness” within the LBCQ. The two
subjective tools appear to have different advantages, with the
LBCQ requesting sensations of both swelling and heaviness,
while the MST provides cues to aid consideration of the
question. If those responding yes to either tool are combined,
the subjectively assessed prevalence estimate reaches 27.2%,
only 1% greater than the objectively determined estimate.
Both choice of items and the way the items are phrased
should be carefully considered in subjective classification of
lymphedema.
When considering the second research question of
whether the three different measurement tools identify the
same subsample of subjects as having lymphedema, analysis
demonstrated that the three tools identified different sub-
groups. Statistical analysis demonstrated little consistency
between perometry and either of the questionnaires and
only moderate agreement between the questionnaires. There
have been suggestions previously that self-report does not
accurately reflect the presence of lymphedema [27]; how-
ever, others believe that subjective assessments can identify
early indicators of lymphedema before objectively identified
changes occur [5, 28]. In response to this, a latent or subclin-
ical stage has been added to the classification of lymphedema
by the International Society of Lymphology [29].
When exploring sensitivity and specificity of lym-
phedema diagnosis, with the objective measure used as a
reference, a relatively high percentage of potentially “positive”
cases were not detected by either the LBCQ or MST, while
these tools also identified individuals as having lymphedema
who were not detected by objective testing. A previous
study also reported that when comparedwithmultifrequency
electrical impedance, self-report was found to have a sensi-
tivity of 65% but demonstrated an unacceptable number of
“false negatives” and “false positives” [10]. Low sensitivity is
concerning in relation to early and appropriate intervention,
while low specificity could result in inappropriate resource
usage and unnecessary anxiety for patients. In the current
study, the former is of the greatest concern.
The differences between objective and subjective tools
may reflectmeasurement of different aspects of amultifaceted
condition—physical, cognitive, and affective [1]. Therefore it
may not be meaningful to compare objective and subjective
tools, if they measure different dimensions. Instead, it may
be more valuable to consider which method is best suited for
early detection of lymphedema to enable timely intervention
and which is best for monitoring changes in the condition
in response to treatment. The latter may depend on whether
improvement in the condition is best reflected by reduction in
swelling, improvement in function, or adaptation in coping.
As there is no clear evidence that the amount of swelling cor-
relates with the amount of distress, it may be more valuable
to monitor subjective experiences of the condition over time
[5, 17]. This is supported by the study finding that quality
of life scores differed significantly between those subjectively
classified as having or not having lymphedema. This was not
evident for objective classification, which is inconsistent with
the existing literature that found significant differences in
quality of life scores between those objectively identified as
having or not having lymphedema [17, 18]. Subjective tools
may provide a better reflection of the diversity of physical,
functional, social, and psychological symptoms and more
strongly reflect the negative relationship between quality of
life and lymphedema.
This study made use of a single objective measure and
classification of lymphedema, which as previously has been
identified to be conservative [11]; future work may benefit
from the inclusion of more than one objective system of
measuring and classifying lymphedema. It is also important
to note that a limitation of this cross-sectional study was
that objectivemeasurement and classification of lymphedema
relied on bilateral limb comparisons, rather than changes
in limb volume over time. This means that normal bilateral
asymmetries were not accounted for [1].
When arriving at decisions relating to appropriate tools
for identifying andmonitoring lymphedema over time, itmay
be beneficial to combine approaches, as suggested previously
[1]. Tracking limb volume may give useful information about
the efficacy of specific interventions that focus on reduc-
ing and maintaining limb volume. Meanwhile, subjective
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symptom assessment may allow identification of early symp-
toms and timely referral for management.
5. Conclusion
In this study between one in four and one in five women
developed lymphedema after breast cancer treatment. Objec-
tive measurement was found to provide higher prevalence
estimates than either of the two subjective tools, although
no statistically significant differences were found. Poor agree-
ment between methods was found between subjective tools
and objective ones, while moderate agreement was found
between subjective tools. Sensitivity of the subjective tools,
compared with objective ones, was not high, while specificity
was better. Quality of life subscale scores did not differentiate
significantly between those with and without lymphedema
when using objective classification, but did when using
either subjective tool. The results support previous sugges-
tions in the literature that lymphedema is multifaceted and
that objective tools focus on the physical, while subjective
tools reflect the functional and emotional dimensions. This
supports the use of both objective and subjective tools in
determining early signs of lymphedema development and in
monitoring different dimensions of the experience following
rehabilitation interventions. Further research is needed to
establish an ideal battery of measures that would enable
future comparisons between prevalence estimates and studies
of treatment efficacy.
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